Refining detection of drug-induced proarrhythmia: QT interval and TRIaD.
暂无分享,去创建一个
[1] Marek Malik,et al. Practical use of T wave morphology assessment. , 2002, Cardiac electrophysiology review.
[2] L. Demay,et al. Notched T Waves on Holter Recordings Enhance Detection of Patients With LQT2 (HERG) Mutations , 2001, Circulation.
[3] F. Charpentier,et al. Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol. , 1999, Cardiovascular research.
[4] Jean-Pierre Valentin,et al. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. , 2004, Journal of pharmacological and toxicological methods.
[5] N. El-Sherif,et al. TU Alternans, Long QTU, and Torsade de Pointes: Clinical and Experimental Observations , 1992 .
[6] A Garfinkel,et al. Patterns of wave break during ventricular fibrillation in isolated swine right ventricle. , 2001, American journal of physiology. Heart and circulatory physiology.
[7] B. Singh,et al. Control of cardiac arrhythmias by lengthening repolarization , 1988 .
[8] T. Ohe,et al. Torsade de pointes with a normal QT interval associated with hypokalemia: a case report. , 2001, Japanese circulation journal.
[9] M. Radford,et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. , 1996, Circulation.
[10] Jules C Hancox,et al. Inhibitory actions of the selective serotonin re‐uptake inhibitor citalopram on HERG and ventricular L‐type calcium currents , 2002, FEBS letters.
[11] Marc A. Vos,et al. Electrophysiological Safety of Sertindole in Dogs with Normal and Remodeled Hearts , 2003, Journal of Pharmacology and Experimental Therapeutics.
[12] D. Wysowski,et al. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions , 2001, American Journal of Gastroenterology.
[13] D. Zipes,et al. Alpha-adrenoceptor stimulation and blockade modulates cesium-induced early afterdepolarizations and ventricular tachyarrhythmias in dogs. , 1990, Circulation.
[14] Y. Aizawa,et al. Role of α1-Blockade in Congenital Long QT Syndrome , 2001 .
[15] L. Hondeghem. TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability). , 2005, Novartis Foundation symposium.
[16] J. Morganroth. Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms. , 1993, The American journal of cardiology.
[17] Charles Antzelevitch,et al. Assessing predictors of drug-induced torsade de pointes. , 2003, Trends in pharmacological sciences.
[18] Charles Antzelevitch,et al. Amplified Transmural Dispersion of Repolarization as the Basis for Arrhythmogenesis in a Canine Ventricular-Wedge Model of Short-QT Syndrome , 2004, Circulation.
[19] Jiesheng Kang,et al. Cardiac Ion Channel Effects of Tolterodine , 2004, Journal of Pharmacology and Experimental Therapeutics.
[20] H L Greene,et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.
[21] A. Moss. T-wave patterns associated with the hereditary long QT syndrome. , 2002, Cardiac electrophysiology review.
[22] J. Daubert,et al. Les torsades de pointe: A propos de 54 cas , 1982 .
[23] A. Camm,et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.
[24] J. Brachmann,et al. Electrocardiographic and Clinical Predictors of Torsades de Pointes Induced by Almokalant Infusion in Patients with Chronic Atrial Fibrillation or Flutter: A Prospective Study , 1998, Pacing and clinical electrophysiology : PACE.
[25] S. Connolly,et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT , 1997, The Lancet.
[26] H. Morita,et al. Nicorandil abolished repolarisation alternans in a patient with idiopathic long QT syndrome , 1999, Heart.
[27] K. Kugiyama,et al. Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model. , 2002, Circulation journal : official journal of the Japanese Circulation Society.
[28] G. Kay,et al. Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. , 1983, Journal of the American College of Cardiology.
[29] M. Lesch,et al. Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy. , 1989, Annals of internal medicine.
[30] J. M. Di Diego,et al. Cisapride-Induced Transmural Dispersion of Repolarization and Torsade de Pointes in the Canine Left Ventricular Wedge Preparation During Epicardial Stimulation , 2003, Circulation.
[31] A. Moss,et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. , 1995, Circulation.
[32] P. Coumel,et al. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. , 1995, Circulation.
[33] M. Nagashima,et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death , 2003, Heart.
[34] G. Gintant,et al. The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced Arrhythmogenesis , 2001, Journal of cardiovascular pharmacology.
[35] R. Brugada,et al. Further Insights into the Effect of Quinidine in Short QT Syndrome Caused by a Mutation in HERG , 2005, Journal of cardiovascular electrophysiology.
[36] Effect of Phenylephrine Provocation on Dispersion of Repolarization in Congenital Long QT Syndrome , 2003, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.
[37] S. Hohnloser,et al. Amiodarone-associated Proarrhythmic Effects: A Review with Special Reference to Torsade de Pointes Tachycardia , 1994, Annals of Internal Medicine.
[38] B. Grubb. The use of oral labetalol in the treatment of arrhythmias associated with the long QT syndrome. , 1991, Chest.
[39] S. Priori,et al. A Novel Form of Short QT Syndrome (SQT3) Is Caused by a Mutation in the KCNJ2 Gene , 2005, Circulation research.
[40] Hua-rong Lu,et al. Detection of Proarrhythmia in the Female Rabbit Heart: , 2003, Journal of cardiovascular electrophysiology.
[41] D. Raunig,et al. The Relationship of Clinical QT Prolongation to Outcome in the Conscious Dog Using a Beat-to-Beat QT-RR Interval Assessment , 2002, Journal of Pharmacology and Experimental Therapeutics.
[42] I Kodama,et al. Open channel block of HERG K(+) channels by vesnarinone. , 2001, Molecular pharmacology.
[43] Suppression of Torsades de Pointes with verapamil in patients with atrio-ventricular block. , 1991, European heart journal.
[44] C Antzelevitch,et al. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. , 1998, Circulation.
[45] Gary A Gintant,et al. The Utility of hERG and Repolarization Assays in Evaluating Delayed Cardiac Repolarization: Influence of Multi-Channel Block , 2004, Journal of cardiovascular pharmacology.
[46] N. Hasebe,et al. A Case of a Short‐Coupled Variant of Torsades De Pointes with Electrical Storm , 2003, Pacing and clinical electrophysiology : PACE.
[47] Todd Wisialowski,et al. Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. , 2004, European journal of pharmacology.
[48] J. Morganroth. Comparative efficacy and safety of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmias. , 1987, The American journal of cardiology.
[49] J. Brugada,et al. Idiopathic Short QT Interval:A New Clinical Syndrome? , 2001, Cardiology.
[50] M. Scheinman,et al. Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval. , 1986, Circulation.
[51] A. Moss,et al. T wave alternans in idiopathic long QT syndrome. , 1994, Journal of the American College of Cardiology.
[52] P. Denes,et al. Clinical, electrocardiographic and follow-up observations in patients having ventricular fibrillation during Holter monitoring. Role of quinidine therapy. , 1981, The American journal of cardiology.
[53] D J Triggle,et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. , 2001, Molecular pharmacology.
[54] D. Roden. Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.
[55] T. Colatsky,et al. What happens when cardiac Na channel function is compromised? 2. Numerical studies of the vulnerable period in tissue altered by drugs. , 2003, Cardiovascular research.
[56] M R Franz,et al. Sudden cardiac death and polymorphous ventricular tachycardia in patients with normal QT intervals and normal systolic cardiac function. , 1995, The American journal of cardiology.
[57] W. Shen,et al. Catecholamine-induced T-wave lability in congenital long QT syndrome: a novel phenomenon associated with syncope and cardiac arrest. , 2003, Mayo Clinic proceedings.
[58] Gea-Ny Tseng,et al. IKr: The hERG Channel , 2001 .
[59] M R Franz,et al. Bridging the Gap Between Basic and Clinical Electrophysiology: , 1994, Journal of cardiovascular electrophysiology.
[60] S. Priori,et al. Differential effects of beta-blockade on dispersion of repolarization in the absence and presence of sympathetic stimulation between the LQT1 and LQT2 forms of congenital long QT syndrome. , 2002, Journal of the American College of Cardiology.
[61] Wataru Shimizu,et al. Classification and mechanism of Torsade de Pointes initiation in patients with congenital long QT syndrome. , 2004 .
[62] A. Camm,et al. Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? , 1998, The American journal of cardiology.
[63] C. Obejero-Paz,et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. , 2004, Molecular pharmacology.
[64] I Kodama,et al. Carvedilol blocks the repolarizing K+ currents and the L-type Ca2+ current in rabbit ventricular myocytes. , 1999, European journal of pharmacology.
[65] N. Urao,et al. Idiopathic long QT syndrome with early afterdepolarization induced by epinephrine. Acase report. , 2004, Circulation journal : official journal of the Japanese Circulation Society.
[66] C. Antzelevitch,et al. Effects of Sodium Channel Block with Mexiletine to Reverse Action Potential Prolongation in In Vitro Models of the Long QT Syndrome , 1997, Journal of cardiovascular electrophysiology.
[67] P. Coumel,et al. Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. , 1994, Circulation.
[68] T. Meinertz. Mibefradil : a drug which may enhance the propensity for the development of abnormal QT prolongation , 2001 .
[69] P. Sager,et al. Frequency-dependent electrophysiologic effects of amiodarone in humans. , 1993, Circulation.
[70] S. Priori,et al. Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome. , 2001, Journal of the American College of Cardiology.
[71] G. Breithardt,et al. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. , 2002, The Journal of pharmacology and experimental therapeutics.
[72] G. Breithardt,et al. Clinical aspects of ventricular arrhythmias associated with QT prolongation , 2001 .
[73] Bertram Pitt,et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.
[74] W. Brady,et al. Prevalence, therapeutic response, and outcome of ventricular tachycardia in the out-of-hospital setting: a comparison of monomorphic ventricular tachycardia, polymorphic ventricular tachycardia, and torsades de pointes. , 1999, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.
[75] Y. Ruan,et al. Short-coupled variant of torsade de pointes. , 2001, Journal of Tongji Medical University = Tong ji yi ke da xue xue bao.
[76] M. Iliou,et al. [Torsades de pointes]. , 1993, Archives des maladies du coeur et des vaisseaux.
[77] H. Kennedy,et al. Torsades de pointes associated with drugs and toxins: recognition and management. , 1987, American heart journal.
[78] Torsade de Pointes , 2003 .
[79] A. Camm,et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. , 1999, The New England journal of medicine.
[80] R. Lazzara,et al. Early Afterdepolarizations Produced by d,1‐Sotalol and Clofilium , 1997, Journal of cardiovascular electrophysiology.
[81] A. Moss,et al. Primidone in the treatment of the long QT syndrome: QT shortening and ventricular arrhythmia suppression. , 1980, Annals of internal medicine.
[82] Yoshihisa Kurachi,et al. [Evaluation of pro-arrhythmic risk of drugs due to QT interval prolongation by the HERG expression system]. , 2002, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.
[83] N. White,et al. Quinine and Quinidine: A Comparison of EKG Effects During the Treatment of Malaria , 1983, Journal of cardiovascular pharmacology.
[84] B. Surawicz. Torsades de pointes: unanswered questions. , 2002, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.
[85] D. Roden,et al. Drug Block of I Kr : Model Systems and Relevance to Human Arrhythmias , 2001, Journal of cardiovascular pharmacology.
[86] CHARLES ANTZELEVITCH,et al. The M Cell: , 1999, Journal of cardiovascular electrophysiology.
[87] M. Franz,et al. Electrophysiological basis of QT dispersion measurements. , 2000, Progress in cardiovascular diseases.
[88] Akihiko Kandori,et al. Reconstruction of action potential of repolarization in patients with congenital long-QT syndrome. , 2004, Physics in medicine and biology.
[89] R. Lux,et al. T-wave alternans in LQTS: repolarization-rate dynamics from digital 12-lead Holter data. , 2001, Journal of electrocardiology.
[90] P. Hoffmann,et al. Blinded Test in Isolated Female Rabbit Heart Reliably Identifies Action Potential Duration Prolongation and Proarrhythmic Drugs: Importance of Triangulation, Reverse Use Dependence, and Instability , 2003, Journal of cardiovascular pharmacology.
[91] A. Camm,et al. Mortality in Patients After a Recent Myocardial Infarction: A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification , 2004, Circulation.
[92] P. Nihoyannopoulos,et al. Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy , 1999, Heart.
[93] W. Shimizu,et al. Exercise Stress Test Amplifies Genotype-Phenotype Correlation in the LQT1 and LQT2 Forms of the Long-QT Syndrome , 2003, Circulation.
[94] Milan Stengl,et al. Increased Short-Term Variability of Repolarization Predicts d-Sotalol–Induced Torsades de Pointes in Dogs , 2004, Circulation.
[95] E. Prystowsky,et al. Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. , 1988, The New England journal of medicine.
[96] J. M. Di Diego,et al. Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent , 2004, Journal of cardiovascular pharmacology and therapeutics.
[97] T. Tomson,et al. Phenytoin and phenobarbital inhibit human HERG potassium channels , 2003, Epilepsy Research.
[98] A. Katchman,et al. The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. , 1998, The Journal of pharmacology and experimental therapeutics.
[99] P. Kowey,et al. Electrophysiologic Effects of SB-237376: A New Antiarrhythmic Compound with Dual Potassium and Calcium Channel Blocking Action , 2003, Journal of cardiovascular pharmacology.
[100] Dierk Thomas,et al. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. , 2002, The Journal of pharmacology and experimental therapeutics.
[101] P Maison-Blanche,et al. Time- and rate-dependent alterations of the QT interval precede the onset of torsade de pointes in patients with acquired QT prolongation. , 1997, Journal of the American College of Cardiology.
[102] Craig T. January,et al. Early Afterdepolarizations: Mechanism of Induction and Block A Role for L‐Type Ca2+ Current , 1989, Circulation research.
[103] Jun Chen,et al. A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[104] C. Antzelevitch,et al. Cellular and ionic basis for T-wave alternans under long-QT conditions. , 1999, Circulation.
[105] D. DeMets,et al. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.
[106] R. Califf,et al. Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. , 2002, American heart journal.
[107] G. Breithardt,et al. Divergent Proarrhythmic Potential of Macrolide Antibiotics Despite Similar QT Prolongation: Fast Phase 3 Repolarization Prevents Early Afterdepolarizations and Torsade de Pointes , 2002, Journal of Pharmacology and Experimental Therapeutics.
[108] T J Campbell,et al. Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate , 1999, British journal of pharmacology.
[109] A. Garfinkel,et al. Chaos and the transition to ventricular fibrillation: a new approach to antiarrhythmic drug evaluation. , 1999, Circulation.
[110] Wojciech Zareba,et al. Repolarization Dynamics in Patients with Long QT Syndrome , 2002, Journal of cardiovascular electrophysiology.
[111] P. Kowey,et al. Phase 2 Early Afterdepolarization as a Trigger of Polymorphic Ventricular Tachycardia in Acquired Long-QT Syndrome: Direct Evidence From Intracellular Recordings in the Intact Left Ventricular Wall , 2001, Circulation.
[112] A. V. van Ginneken,et al. Mutation in the KCNQ1 Gene Leading to the Short QT-Interval Syndrome , 2004, Circulation.
[113] M. Zaniboni,et al. Beat-to-beat repolarization variability in ventricular myocytes and its suppression by electrical coupling. , 2000, American journal of physiology. Heart and circulatory physiology.
[114] H. Huikuri. Dispersion of Repolarisation and the Autonomic System—Can We Predict Torsade de Pointes? , 2002, Cardiovascular Drugs and Therapy.
[115] C. Antzelevitch,et al. Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. , 2000, Circulation.
[116] B. Katzung,et al. Effects of Extracellular Potassium on Ventricular Automaticity and Evidence for a Pacemaker Current in Mammalian Ventricular Myocardium , 1977, Circulation research.
[117] A. Camm,et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT , 1997, The Lancet.
[118] Martin Borggrefe,et al. Congenital Short QT Syndrome and Implantable Cardioverter Defibrillator Treatment: , 2003, Journal of cardiovascular electrophysiology.
[119] M. Shoda,et al. Electrophysiological characteristic of a patient exhibiting the short-coupled variant of torsade de pointes. , 2001, Journal of electrocardiology.
[120] Y. Aizawa,et al. Nicorandil suppresses a hump on the monophasic action potential and torsade de pointes in a patient with idiopathic long QT syndrome. , 1995, Japanese heart journal.
[121] R. Zimlichman,et al. Polymorphous ventricular tachycardia. , 1983, The American journal of cardiology.
[122] M. Janse,et al. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials , 1997, The Lancet.
[123] Shien-Fong Lin,et al. Spatial heterogeneity of action potential alternans during global ischemia in the rabbit heart. , 2003, American journal of physiology. Heart and circulatory physiology.
[124] M. Messier,et al. Predictive Factors of Ventricular Fibrillation Triggered by Pause‐Dependent Torsades de Pointes Associated with Acquired Long QT Interval: , 2000, Journal of cardiovascular electrophysiology.
[125] H. Morita,et al. Nicorandil attenuates both temporal and spatial repolarization alternans. , 2000, Journal of electrocardiology.
[126] Hua-rong Lu,et al. Drug-induced long QT in isolated rabbit Purkinje fibers: importance of action potential duration, triangulation and early afterdepolarizations. , 2002, European journal of pharmacology.
[127] Lauri Toivonen,et al. Ambulatory Electrocardiographic Evidence of Transmural Dispersion of Repolarization in Patients With Long-QT Syndrome Type 1 and 2 , 2002, Circulation.
[128] W. Shen,et al. Catecholamine‐Provoked Microvoltage T Wave Alternans in Genotyped Long QT Syndrome , 2003, Pacing and clinical electrophysiology : PACE.
[129] L. Gettes,et al. T Wave Alternans and Torsades de Pointes After the Use of Intravenous Pentamidine , 2002, Journal of cardiovascular electrophysiology.
[130] B. Katzung,et al. Cardiac ventricular automaticity induced by current of injury , 1975, Pflügers Archiv European Journal of Physiology.
[131] Bente Brendorp,et al. A Benefit-Risk Assessment of Class III Antiarrhythmic Agents , 2002, Drug safety.
[132] S. Swiryn,et al. Familial inducible torsade de pointes with normal QT interval. , 1983, European heart journal.
[133] K. Sunagawa,et al. Excessive Increase in QT Interval and Dispersion of Repolarization Predict Recurrent Ventricular Tachyarrhythmia after Amiodarone , 2004, Pacing and clinical electrophysiology : PACE.
[134] H. Doval,et al. Randomised trial of low-dose amiodarone in severe congestive heart failure , 1994, The Lancet.
[135] B. Fermini,et al. The impact of drug-induced QT interval prolongation on drug discovery and development , 2003, Nature Reviews Drug Discovery.
[136] P. Puech,et al. Torsades de Pointe , 1988 .
[137] A. Bénardeau,et al. Effects of the T-type Ca(2+) channel blocker mibefradil on repolarization of guinea pig, rabbit, dog, monkey, and human cardiac tissue. , 2000, The Journal of pharmacology and experimental therapeutics.
[138] Martin Borggrefe,et al. Short QT Syndrome: A Familial Cause of Sudden Death , 2003, Circulation.
[139] S. Olsson,et al. Monophasic Action Potentials: , 1994, Journal of cardiovascular electrophysiology.
[140] C. Antzelevitch,et al. Antiarrhythmic Effects of Ranolazine in a Guinea Pig in Vitro Model of Long-QT Syndrome , 2004, Journal of Pharmacology and Experimental Therapeutics.
[141] R. Shah,et al. Pharmacogenetic Aspects of Drug-Induced Torsade de Pointes , 2004, Drug safety.
[142] A. Camm,et al. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. , 1999, Circulation.
[143] M. Rosen,et al. Chronic in vivo and in vitro effects of amiodarone on guinea pig hearts. , 1996, The Journal of pharmacology and experimental therapeutics.
[144] J. Mason,et al. Risk Factors for Tachycardia Events Caused by Antiarrhythmic Drugs: Experience From the ESVEM Trial , 1998, Journal of cardiovascular pharmacology and therapeutics.
[145] C. January,et al. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. , 1999, Circulation research.
[146] Wataru Shimizu,et al. Cellular mechanisms underlying the long QT syndrome. , 2002, Current opinion in cardiology.
[147] C R Benedict,et al. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. , 2000, The Journal of pharmacology and experimental therapeutics.
[148] J. Brugada,et al. Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG , 2003, Circulation.
[149] G. Duker,et al. Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic , 2001, Circulation.
[150] D. Snyders,et al. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. , 1990, Circulation.
[151] S. O’Donoghue,et al. Levofloxacin Induced Polymorphic Ventricular Tachycardia with Normal QT Interval , 2001, Pacing and clinical electrophysiology : PACE.
[152] P. Kowey,et al. Ventricular fibrillation during coronary angiography: the precatheterization QT interval. , 1987, Journal of electrocardiology.
[153] J. Rey,et al. [Torsades de pointe. Apropos of 60 cases]. , 1985, Annales de cardiologie et d'angeiologie.
[154] A. Camm,et al. Effect of amiodarone on the descending limb of the T wave. , 2003, The American journal of cardiology.
[155] L. Makarov,et al. [QT interval shortening in families with history of sudden death at young age]. , 2004, Kardiologiia.
[156] S. Hohnloser,et al. Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans. Results of a prospective, double-blind, randomized study. , 2001, Journal of the American College of Cardiology.
[157] A J Moss,et al. ECG features of microvolt T-wave alternans in coronary artery disease and long QT syndrome patients. , 1998, Journal of electrocardiology.
[158] Bramahn . Singh,et al. Antiarrhythmic and Proarrhythmic Properties of QT-Prolonging Antianginal Drugs , 2004, Journal of cardiovascular pharmacology and therapeutics.
[159] C Antzelevitch,et al. Cellular basis for QT dispersion. , 1998, Journal of electrocardiology.
[160] R. Lazzara. Amiodarone and torsade de pointes. , 1989, Annals of internal medicine.
[161] A. Keren,et al. Etiology, Warning Signs and Therapy of Torsade de Pointes: A Study of 10 Patients , 1981, Circulation.
[162] C. Antzelevitch,et al. Unique Topographical Distribution of M Cells Underlies Reentrant Mechanism of Torsade de Pointes in the Long-QT Syndrome , 2002, Circulation.
[163] L. Hondeghem,et al. Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. , 2001, Cardiovascular research.
[164] C. White,et al. Amiodarone in the New AHA Guidelines for Ventricular Tachyarrhythmias , 2001, The Annals of pharmacotherapy.
[165] Y. Kuryshev,et al. Pentamidine-Induced Long QT Syndrome and Block of hERG Trafficking , 2005, Journal of Pharmacology and Experimental Therapeutics.
[166] M. Scheinman,et al. Evaluation and management of patients with polymorphic ventricular tachycardia. , 1993, Cardiology clinics.
[167] E. Williams. Classification of Antiarrhythmic Actions , 1989 .
[168] T. Fraker,et al. Polymorphous ventricular tachycardia provoked by lidocaine. , 1985, The American journal of cardiology.
[169] S. Swiryn,et al. Torsade de pointes due to quinidine: observations in 31 patients. , 1984, American heart journal.
[170] N. Yoshimoto,et al. Nicorandil, a Potassium Channel Opener, Abolished Torsades de Pointes in a Patient with Complete Atrioventricular Block , 1999, Pacing and clinical electrophysiology : PACE.
[171] H. Morita,et al. Early Afterdepolarization Abolished by Potassium Channel Opener in a Patient with Idiopathic Long QT Syndrome , 1995, Journal of cardiovascular electrophysiology.
[172] R. Shah,et al. The significance of QT interval in drug development. , 2002, British journal of clinical pharmacology.
[173] E. Zitron,et al. Rapid component I(Kr) of the guinea-pig cardiac delayed rectifier K(+) current is inhibited by beta(1)-adrenoreceptor activation, via cAMP/protein kinase A-dependent pathways. , 2002, Cardiovascular research.